ZEVRA THERAPEUTICS INC (ZVRA) Stock Price, Quote, News and Overview
NASDAQ:ZVRA - Nasdaq - US4884452065 - Common Stock - Currency: USD
ZVRA Quote, Performance and Key Statistics
8.33
-0.12 (-1.42%)
The current stock price of ZVRA is 8.33 USD. In the past month the price increased by 15.21%. In the past year, price increased by 79.14%.
ZVRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.28 | 681.79B | ||
| JNJ | JOHNSON & JOHNSON | 15.17 | 366.76B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.22 | 304.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.46 | 220.95B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16 | 218.21B | ||
| MRK | MERCK & CO. INC. | 9.78 | 191.27B | ||
| PFE | PFIZER INC | 7.22 | 131.79B | ||
| SNY | SANOFI-ADR | 11.79 | 126.53B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.4 | 95.59B | ||
| GSK | GSK PLC-SPON ADR | 8.84 | 79.50B | ||
| ZTS | ZOETIS INC | 27.48 | 73.64B | ||
| HLN | HALEON PLC-ADR | 22.96 | 50.66B |
Related stock screener links
About ZVRA
Company Profile
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Company Info
ZEVRA THERAPEUTICS INC
1180 Celebration Boulevard, Suite 103
Celebration FLORIDA US
Employees: 59
Phone: 13219393416
ZEVRA THERAPEUTICS INC / ZVRA FAQ
What is the stock price of ZEVRA THERAPEUTICS INC today?
The current stock price of ZVRA is 8.33 USD. The price decreased by -1.42% in the last trading session.
What is the ticker symbol for ZEVRA THERAPEUTICS INC stock?
The exchange symbol of ZEVRA THERAPEUTICS INC is ZVRA and it is listed on the Nasdaq exchange.
On which exchange is ZVRA stock listed?
ZVRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZEVRA THERAPEUTICS INC stock?
14 analysts have analysed ZVRA and the average price target is 22.73 USD. This implies a price increase of 172.89% is expected in the next year compared to the current price of 8.33. Check the ZEVRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZEVRA THERAPEUTICS INC worth?
ZEVRA THERAPEUTICS INC (ZVRA) has a market capitalization of 455.48M USD. This makes ZVRA a Small Cap stock.
How many employees does ZEVRA THERAPEUTICS INC have?
ZEVRA THERAPEUTICS INC (ZVRA) currently has 59 employees.
What are the support and resistance levels for ZEVRA THERAPEUTICS INC (ZVRA) stock?
ZEVRA THERAPEUTICS INC (ZVRA) has a support level at 8.32 and a resistance level at 8.54. Check the full technical report for a detailed analysis of ZVRA support and resistance levels.
Is ZEVRA THERAPEUTICS INC (ZVRA) expected to grow?
The Revenue of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 325.15% in the next year. Check the estimates tab for more information on the ZVRA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZEVRA THERAPEUTICS INC (ZVRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZVRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZVRA, evaluating the profitability, health, valuation and growth aspects
- ZEVRA THERAPEUTICS INC (ZVRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZEVRA THERAPEUTICS INC (ZVRA) Sales and EPS estimates to see what analysts future expectations are.
- ZEVRA THERAPEUTICS INC (ZVRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZEVRA THERAPEUTICS INC (ZVRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZEVRA THERAPEUTICS INC (ZVRA) Stock Chart to make your own analysis
- ZEVRA THERAPEUTICS INC (ZVRA) Latest news and press-releases to stay up to date.
Does ZEVRA THERAPEUTICS INC (ZVRA) stock pay dividends?
ZVRA does not pay a dividend.
When does ZEVRA THERAPEUTICS INC (ZVRA) report earnings?
ZEVRA THERAPEUTICS INC (ZVRA) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of ZEVRA THERAPEUTICS INC (ZVRA)?
ZEVRA THERAPEUTICS INC (ZVRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.92).
What is the Short Interest ratio of ZEVRA THERAPEUTICS INC (ZVRA) stock?
The outstanding short interest for ZEVRA THERAPEUTICS INC (ZVRA) is 10.42% of its float. Check the ownership tab for more information on the ZVRA short interest.
ZVRA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZVRA. When comparing the yearly performance of all stocks, ZVRA is one of the better performing stocks in the market, outperforming 94.28% of all stocks.
ZVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZVRA. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative.
ZVRA Financial Highlights
Over the last trailing twelve months ZVRA reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS decreased by -42.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.26% | ||
| ROE | -224.24% | ||
| Debt/Equity | 1.46 |
ZVRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ZVRA. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 129.85% and a revenue growth 325.15% for ZVRA